布鲁顿酪氨酸激酶——免疫介导炎症性疾病的新靶点?
布鲁顿酪氨酸激酶(BTK)在B细胞和髓系细胞多种表面受体下游信号通路中起关键作用,先天性缺陷导致X连锁无丙种球蛋白血症,BTK抑制剂已获批用于部分B细胞恶性肿瘤并已在多种自身免疫和炎症性疾病中研究。在风湿病中,类风湿关节炎和系统性红斑狼疮的结果令人失望,但干燥综合征有一些疗效证据;多发性硬化、慢性自发性荨麻疹以及可能寻常型天疱疮的数据更为积极。第一代BTK抑制剂安全性包括心脏毒性、高血压、出血和皮疹,第二代抑制剂安全性更可接受但某些情况下仍观察到剂量限制性毒性。
要点
- BTK抑制剂在类风湿关节炎和系统性红斑狼疮中结果令人失望,干燥综合征有一些疗效证据。
- 多发性硬化、慢性自发性荨麻疹及可能寻常型天疱疮中数据更为积极。
- 第一代BTK抑制剂安全性包括心脏毒性、高血压、出血和皮疹,第二代安全性更可接受但某些情况仍有剂量限制性毒性。
核心结论
- BTK抑制剂在风湿病中类风湿关节炎和系统性红斑狼疮结果令人失望,干燥综合征有一些疗效证据,不同疾病疗效差异的原因尚未完全阐明,可能反映疾病对B细胞和髓系细胞不同信号通路的依赖及其对BTK抑制剂的相对敏感性。
研究设计与样本
- 综述类文章,检索范围原文未报告。
主要发现
- BTK抑制剂在类风湿关节炎和系统性红斑狼疮中结果令人失望,在干燥综合征有一些疗效证据。
- 多发性硬化、慢性自发性荨麻疹以及可能寻常型天疱疮中数据更为积极,BTK抑制剂也可能在食物过敏等严重过敏性疾病中找到作用。
- 第一代BTK抑制剂安全性包括心脏毒性、高血压、出血和皮疹,第二代抑制剂安全性更可接受但某些情况包括类风湿关节炎仍观察到剂量限制性毒性。
关键数值与推荐
- 原文未报告具体疗效数值或推荐等级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 不同疾病中疗效差异的原因尚未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein that plays a key role in signalling pathways downstream of diverse surface receptors in B-cells and myeloid cells. These include the B-cell receptor itself, Fc receptors including FcεRI, toll-like receptors and chemokine receptors. Congenital deficiency of BTK causes X-linked agammaglobulinaemia because of B-cell developmental block, and BTK inhibitors (BTKi) are approved for the treatment of certain B-cell malignancies. They have also been studied in a variety of autoimmune and inflammatory diseases. In rheumatic conditions, results have been disappointing in rheumatoid arthritis (RA) and systemic lupus erythematosus but with some evidence for efficacy in Sjogren's syndrome. Data are more positive in multiple sclerosis, as well as in the cutaneous disease chronic spontaneous urticaria and possibly pemphigus vulgaris. BTKi may also find a role in severe allergic disease such as food allergy. First generation BTKi had a safety profile that included cardiotoxicity, hypertension, haemorrhage and rash. Second generation inhibitors have a more acceptable safety profile although dose-limiting toxicity is still observed in some conditions, including RA. Pharmacokinetic factors aside, the variable efficacy in different diseases is not fully explained but is likely to reflect disease dependence on different pathways in B-cells and myeloid cells and their relative sensitivity to BTKi.
引用
- Isaacs JD. Bruton's tyrosine kinase - A new target for immune mediated inflammatory diseases? Semin Arthritis Rheum. 2025. PMID: 40023669. doi:10.1016/j.semarthrit.2025.152681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。